open access

Vol 90, No 4 (2019)
REVIEW PAPERS Gynecology
Published online: 2019-04-29
Get Citation

Semaphorin 3A (SEMA3A), protocadherin 9 (PCdh9), and S100 calcium binding protein A3 (S100A3) as potential biomarkers of carcinogenesis and chemoresistance of different neoplasms, including ovarian cancer — review of literature

Natalia Izycka, Karolina Sterzynska, Radoslaw Januchowski, Ewa Nowak-Markwitz
DOI: 10.5603/GP.2019.0040
·
Pubmed: 31059116
·
Ginekol Pol 2019;90(4):223-227.

open access

Vol 90, No 4 (2019)
REVIEW PAPERS Gynecology
Published online: 2019-04-29

Abstract

Ovarian cancer is the fifth leading cause of cancer-related deaths in women. Its high mortality rate results from lack of adequate and sensitive methods allowing for the detection of the early stages of the disease, as well as low efficiency of the treatment, caused by the cytotoxic drug resistance of cancer cells. Unfortunately, tumours are able to develop new pathways and protective mechanisms that allow them to survive toxic conditions of chemotherapy. Therefore, intensive search for new genes and proteins involved in resistance to cytotoxic drugs is still needed, especially from a clinical point of view. The article presents an overview of the available literature on the role of semaphorin 3A (SEMA3A), protocadherin 9 (PCDH9), and S100 calcium binding protein A3 (S100A3) in carcinogenesis and chemoresistance of various tumors including ovarian cancer. As it turns out, the role of described genes/proteins is not limited only to their native biological activity but they function also as an oncogenic or suppressor factors in the tumor development. Moreover, they can also play an important role in development of drug resistance, as it was shown in ovarian cancer cell lines.

Abstract

Ovarian cancer is the fifth leading cause of cancer-related deaths in women. Its high mortality rate results from lack of adequate and sensitive methods allowing for the detection of the early stages of the disease, as well as low efficiency of the treatment, caused by the cytotoxic drug resistance of cancer cells. Unfortunately, tumours are able to develop new pathways and protective mechanisms that allow them to survive toxic conditions of chemotherapy. Therefore, intensive search for new genes and proteins involved in resistance to cytotoxic drugs is still needed, especially from a clinical point of view. The article presents an overview of the available literature on the role of semaphorin 3A (SEMA3A), protocadherin 9 (PCDH9), and S100 calcium binding protein A3 (S100A3) in carcinogenesis and chemoresistance of various tumors including ovarian cancer. As it turns out, the role of described genes/proteins is not limited only to their native biological activity but they function also as an oncogenic or suppressor factors in the tumor development. Moreover, they can also play an important role in development of drug resistance, as it was shown in ovarian cancer cell lines.

Get Citation

Keywords

ovarian cancer; carcinogenesis; chemotherapy; drug resistance; semaphorin 3A (SEMA3A); protocadherin 9 (PCDH9); S100 calcium binding protein A3 (S100A3)

About this article
Title

Semaphorin 3A (SEMA3A), protocadherin 9 (PCdh9), and S100 calcium binding protein A3 (S100A3) as potential biomarkers of carcinogenesis and chemoresistance of different neoplasms, including ovarian cancer — review of literature

Journal

Ginekologia Polska

Issue

Vol 90, No 4 (2019)

Pages

223-227

Published online

2019-04-29

DOI

10.5603/GP.2019.0040

Pubmed

31059116

Bibliographic record

Ginekol Pol 2019;90(4):223-227.

Keywords

ovarian cancer
carcinogenesis
chemotherapy
drug resistance
semaphorin 3A (SEMA3A)
protocadherin 9 (PCDH9)
S100 calcium binding protein A3 (S100A3)

Authors

Natalia Izycka
Karolina Sterzynska
Radoslaw Januchowski
Ewa Nowak-Markwitz

References (34)
  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1): 7–30.
  2. Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol. 2006; 60(2): 159–179.
  3. Parmar MKB, Ledermann JA, Colombo N, et al. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 361(9375): 2099–2106.
  4. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007; 25(19): 2811–2818.
  5. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009; 374(9698): 1371–1382.
  6. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003; 8(5): 411–424.
  7. Gottesman MM, Lavi O, Hall MD, et al. Mechanisms of cancer drug resistance. Annu Rev Med. 2002; 53(46): 615–627.
  8. Januchowski R, Sterzyńska K, Zaorska K, et al. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res. 2016; 9(1): 65.
  9. Sterzyńska K, Klejewski A, Wojtowicz K, et al. The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines. Int J Mol Sci. 2018; 19(10).
  10. Sterzyńska K, Klejewski A, Wojtowicz K, et al. Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development. Int J Mol Sci. 2018; 20(1).
  11. Kolodkin AL, Matthes DJ, Goodman CS. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell. 1993; 75(7): 1389–1399.
  12. Jiang H, Qi L, Wang F, et al. Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma. Int J Mol Med. 2015; 35(5): 1374–1380.
  13. Morris LGT, Veeriah S, Chan TA. Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene. 2010; 29(24): 3453–3464.
  14. Huang C, Wang Yi, Huang JH, et al. Sema3A drastically suppresses tumor growth in oral cancer Xenograft model of mice. BMC Pharmacol Toxicol. 2017; 18(1): 55.
  15. Tang C, Gao X, Liu H, et al. Decreased expression of SEMA3A is associated with poor prognosis in gastric carcinoma. Int J Clin Exp Pathol. 2014; 7(8): 4782–4794.
  16. Bagci T, Wu JK, Pfannl R, et al. Autocrine semaphorin 3A signaling promotes glioblastoma dispersal. Oncogene. 2009; 28(40): 3537–3550.
  17. Li K, Chen MK, Li LY, et al. The predictive value of semaphorins 3 expression in biopsies for biochemical recurrence of patients with low- and intermediate-risk prostate cancer. Neoplasma. 2013; 60(6): 683–689.
  18. Staton CA, Shaw LA, Valluru M, et al. Expression of class 3 semaphorins and their receptors in human breast neoplasia. Histopathology. 2011; 59(2): 274–282.
  19. Shen WW, Chen WG, Liu FZ, et al. Breast cancer cells promote osteoblastic differentiation via Sema 3A signaling pathway in vitro. Int J Clin Exp Pathol. 2015; 8(2): 1584–1593.
  20. Yacoub M, Coulon A, Celhay O, et al. Differential expression of the semaphorin 3A pathway in prostatic cancer. Histopathology. 2009; 55(4): 392–398.
  21. Yamada D, Takahashi K, Kawahara K, et al. Autocrine Semaphorin3A signaling is essential for the maintenance of stem-like cells in lung cancer. Biochem Biophys Res Commun. 2016; 480(3): 375–379.
  22. Herman JG, Meadows GG. Increased class 3 semaphorin expression modulates the invasive and adhesive properties of prostate cancer cells. Int J Oncol. 2007; 30(5): 1231–1238.
  23. Neufeld G, Shraga-Heled N, Lange T, et al. Semaphorins in cancer. Front Biosci. 2005; 10: 751–760.
  24. Januchowski R, Sterzyńska K, Zawierucha P, et al. Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines. Oncotarget. 2017; 8(30): 49944–49958.
  25. Świerczewska M, Klejewski A, Brązert M, et al. New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines. Molecules. 2018; 23(4).
  26. Ren S, Wei GH, Liu D, et al. Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. Eur Urol. 2017 [Epub ahead of print].
  27. Chen Y, Xiang H, Zhang Y, et al. Loss of PCDH9 is associated with the differentiation of tumor cells and metastasis and predicts poor survival in gastric cancer. Clin Exp Metastasis. 2015; 32(5): 417–428.
  28. Zhu P, Lv J, Yang Z, et al. Protocadherin 9 inhibits epithelial-mesenchymal transition and cell migration through activating GSK-3β in hepatocellular carcinoma. Biochem Biophys Res Commun. 2014; 452(3): 567–574.
  29. Wang C, Yu G, Liu J, et al. Downregulation of PCDH9 predicts prognosis for patients with glioma. J Clin Neurosci. 2012; 19(4): 541–545.
  30. Świerczewska M, Klejewski A, Wojtowicz K, et al. New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines. Molecules. 2017; 22(10): 1717.
  31. Liu Ji, Li X, Dong GL, et al. In silico analysis and verification of S100 gene expression in gastric cancer. BMC Cancer. 2008; 8: 261.
  32. Liu B, Sun WY, Zhi CY, et al. Role of S100A3 in human colorectal cancer and the anticancer effect of cantharidinate. Exp Ther Med. 2013; 6(6): 1499–1503.
  33. Tao R, Wang ZF, Qiu W, et al. Role of S100A3 in human hepatocellular carcinoma and the anticancer effect of sodium cantharidinate. Exp Ther Med. 2017; 13(6): 2812–2818.
  34. Kang M, Lee HS, Lee YJu, et al. S100A3 suppression inhibits in vitro and in vivo tumor growth and invasion of human castration-resistant prostate cancer cells. Urology. 2015; 85(1): 273.e9–273.15.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl